The 42-month INCISIVE project (1/10/2020 – 31/3/2024) aims to address three major open challenges in order to explore the full potential of AI solutions in cancer imaging:
In order to do that INCISIVE plans to develop and validate:
The INCISIVE models and analytics will utilize various cancer imaging scans, biological data and EHRs, and will be trained with 1 PB of available data provided by 8 partners within the project. INCISIVE solution will be investigated in three validation studies for Lung, Breast and Colorectal Cancer, taking place in 8 sites, from 5 countries (Cyprus, Greece, Italy, Serbia and Spain), with participation of at least 2000 patients and a total duration of 1.5 year.
INCISIVE moves beyond the state of the art, by improving sensitivity and specificity of lower cost scanning methods, accurately predicting the tumour spread, evolution and relapse, enhancing interpretability of results and “democratizing” imaging data.
Timelex acts as a lawyer to the consortium, dealing with all legal aspects as they arise and providing support to consortium partners where needed. Specifically, Timelex will take care of the data protection questions in INCISIVE and the related ethical aspects.